From the World Economic Forum Davos Agenda:

With 9.9 million new cases of dementia globally each year, the type of collective action witnessed during the COVID-19 pandemic is urgently needed.

What policies, practices and partnerships can help to develop new diagnostics and treatments for Alzheimer’s?

This session is associated with the Davos Alzheimer's Collaborative, convened by the Global CEO Initiative (CEOi) and the World Economic Forum.

Speakers:

Ali Velshi, Anchor, NBC News

Michel Vounatsos, Chief Executive Officer, Biogen

Jeff Huber, Chief Executive Officer, Home Instead Inc.

​Amy Goldman, Chief Executive Officer and Chair, GHR Foundation

GHR Foundation is joining forces with industry, other philanthropic partners and the United States National Institutes of Health on a game-changing undertaking – the prevention of Alzheimer’s disease. One important study GHR is supporting is The Mayo Clinic Study of Aging, which is working to define the impact of Alzheimer's on the population and develop a screening approach to identify those at risk.

View a case study on The Mayo Clinic's innovative research by clicking image below.

GHR supports innovative new approaches to address the impact of Alzheimer’s disease. If you are interested in learning more about GHR’s Health Initiative, contact us.

With a focus on Alzheimer’s disease prevention research, GHR Foundation funded a groundbreaking Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) study which may help identify people who are highest risk to develop the disease. This research will also identify treatments – and when to best administer them – to slow or prevent Alzheimer’s. Long-term, the Foundation hopes the A4 study and complementary research will result in FDA approval for Alzheimer’s prevention therapies.

The A4 study team is continuing to develop the clinical partnerships necessary to study 1,000 patients and has created tools to share background with potential participants. GHR Alzheimer’s advisory board member and lead A4 researcher Dr. Reisa Sperling explains the research and how people can get involved in the research in a recent YouTube video. 

GHR looks forward to learning more about the impact of A4 on early detection and treatment of Alzheimer’s disease.